Gradipore board recruits former Sirtex CEO
Tuesday, 26 August, 2003
Former Sirtex Medical CEO Dr Colin Sutton has joined the board of Gradipore as a non-executive director.
According to Gradipore chairman Prof Jeremy Davis, Sutton's breadth of skills and experience will be fundamental to the current focus on the commercialisation of Gradipore's technology.
"His role as CEO of Sirtex Medical, where he took a start-up company through an IPO to a market capitalisation in excess of $273 million in three years was remarkable. This experience, combined with his earlier experience of building a range of businesses involved in the biomedical field make him an ideal addition to the Gradipore board," said Davis in a statement.
In addition to his position on the Gradipore board, Sutton is a non-executive director of cancer diagnostics company Polartechnics.
Sutton retired from his position as CEO of Sirtex at the end of June following the failure of a takeover bid by US company Cephalon.
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
